A phase I study of adenovirus engineered, interleukin 2 (IL-2) secreting, autologous plasma cell vaccination for the treatment of multiple myeloma. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

publication date

  • November 15, 1999

published in